{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:07:51Z","timestamp":1790734071473,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001320","name":"Roswell Park Cancer Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001320","id-type":"DOI","asserted-by":"crossref"}]},{"name":"RPCI-UPCI SPORE"},{"name":"NIH","award":["P50CA159981"],"award-info":[{"award-number":["P50CA159981"]}]},{"name":"NIH","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}]},{"name":"NIH","award":["K01LM012100"],"award-info":[{"award-number":["K01LM012100"]}]},{"name":"NIH","award":["R01HG007377"],"award-info":[{"award-number":["R01HG007377"]}]},{"name":"NIH","award":["T32CA108456"],"award-info":[{"award-number":["T32CA108456"]}]},{"name":"Roswell Park Alliance Foundation"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ygyno.2015.09.011","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T01:13:52Z","timestamp":1442279632000},"page":"228-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5636-0812","authenticated-orcid":false,"given":"Kevin H.","family":"Eng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret M.","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Brian","family":"Szender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ygyno.2015.09.011_bb0005","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.AOG.0000220516.34053.48","article-title":"Diagnosis and management of epithelial ovarian cancer","volume":"107","author":"Bhoola","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.09.011_bb0010","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.6004\/jnccn.2012.0140","article-title":"Ovarian cancer, version 3.2012","volume":"10","author":"Morgan","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ygyno.2015.09.011_bb0015","doi-asserted-by":"crossref","first-page":"497-429","DOI":"10.1155\/2010\/497429","article-title":"Treatment for recurrent ovarian cancer at first relapse","volume":"2010","author":"Ushijima","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.ygyno.2015.09.011_bb0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"S7","key":"10.1016\/j.ygyno.2015.09.011_bb0025","doi-asserted-by":"crossref","first-page":"vii218","DOI":"10.1093\/annonc\/mdq377","article-title":"Optimal treatment for relapsing ovarian cancer","volume":"21","author":"Ledermann","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.09.011_bb0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_5-20","article-title":"Relapsed ovarian cancer: challenges and management for a chronic disease","volume":"7","author":"Armstrong","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2015.09.011_bb0035","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","article-title":"Recurrent ovarian cancer: how important is it to treat disease progrsesion?","volume":"10","author":"Herzog","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.09.011_bb0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","article-title":"Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin","volume":"9","author":"Markman","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.09.011_bb0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population","volume":"10","author":"Markman","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.09.011_bb0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7150\/jca.3.7","article-title":"Progression-free survival decreases with each subsequent therapy in patients presenting for phase I clinical trials","volume":"3","author":"Bailey","year":"2012","journal-title":"J. Cancer"},{"key":"10.1016\/j.ygyno.2015.09.011_bb0055","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","article-title":"Evolution of platinum resistance in high-grade serous ovarian cancer","volume":"12","author":"Cooke","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2015.09.011_bb0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"Bookman","year":"1999","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2015.09.011_bb0065","first-page":"362","article-title":"A current review of targeted therapeutics for ovarian cancer","volume":"149","author":"Campos","year":"2010","journal-title":"J. Oncol."},{"issue":"36","key":"10.1016\/j.ygyno.2015.09.011_bb0070","first-page":"4102","article-title":"Prognosis and conditional disease-free survival among patients with ovarian cancer","volume":"22","author":"Kurta","year":"2014"},{"key":"10.1016\/j.ygyno.2015.09.011_bb0075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ygyno.2015.09.011_bb0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA125 agreed by the Gynecological Cancer Intergroup","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.09.011_bb0085","series-title":"R: A Language and Evironment for Statistical Computing. Vienna, Austria","author":"R Core Team","year":"2014"},{"key":"10.1016\/j.ygyno.2015.09.011_bb0090","series-title":"Applied Survival Analysis","author":"Hosmer","year":"2008"},{"key":"10.1016\/j.ygyno.2015.09.011_bb0095","author":"Hess"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:06:15Z","timestamp":1599555975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815301281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0090825815301281"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.09.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}